Brief: Acurx Says European Medicines Agency Granted SME Designation For Ibezapolstat EU Development
27/02/2024 12:53
Feb 27 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES FDA HAS GRANTED AN END OF PHASE 2 MEETING
FOR
IBEZAPOLSTAT FOR C. DIFFICILE INFECTION AND THE EUROPEAN
MEDICINES AGENCY GRANTED SME DESIGNATION FOR IBEZAPOLSTAT EU
DEVELOPMENT
* ACURX PHARMACEUTICALS INC: END OF PHASE 2 MEETING WITH FDA
IS
NOW CONFIRMED TO OCCUR IN LATE APRIL 2024 TO FINALIZE PHASE 3
DEVELOPMENT PLAN
Source text for Eikon: ID:nPn2PbMx3a
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln